Bg pattern

ROFLUMILAST AUROVITAS 500 micrograms TABLETS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use ROFLUMILAST AUROVITAS 500 micrograms TABLETS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Patient Information: Summary of Product Characteristics

RoflumilastAurovitas 500 micrograms tablets EFG

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Roflumilast Aurovitas and what is it used for
  2. What you need to know before you take Roflumilast Aurovitas
  3. How to take Roflumilast Aurovitas
  4. Possible side effects
  5. Storage of Roflumilast Aurovitas
  6. Contents of the pack and other information

1. What is Roflumilast Aurovitas and what is it used for

This medicinal product contains the active substance roflumilast, which is a phosphodiesterase-4 inhibitor anti-inflammatory. Roflumilast reduces the activity of phosphodiesterase-4, a protein that occurs naturally in the body's cells. When the activity of this protein is reduced, inflammation in the lungs decreases. This helps to stop the narrowing of the airways that occurs in chronic obstructive pulmonary disease (COPD). Therefore, this medicinal product alleviates respiratory problems.

Roflumilast is used for the maintenance treatment of severe COPD in adults who have had frequent exacerbations of COPD symptoms in the past and who have chronic bronchitis. COPD is a chronic lung disease that results in the narrowing of the airways (obstruction) and swelling and irritation of the walls of the small airways in the lungs (inflammation).

This leads to symptoms such as coughing, wheezing, chest tightness, or difficulty breathing. Roflumilast should be used in conjunction with bronchodilators.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you take Roflumilast Aurovitas

Do not take Roflumilast Aurovitas

  • if you are allergic to roflumilast or any of the other ingredients of this medicinal product (listed in section 6)

if you have moderate or severe liver problems.

Warnings and precautions

Consult your doctor or pharmacist before starting treatment with Roflumilast Aurovitas.

Sudden episodes of shortness of breath (dyspnea)

Roflumilast is not indicated for the treatment of acute bronchospasm (sudden episodes of shortness of breath). To alleviate a sudden episode of shortness of breath, it is essential that your doctor provides you with another medicinal product that you should always carry with you to manage such episodes. Roflumilast will not help in these situations.

Weight

You should check your weight periodically. Consult your doctor if, while taking this medicinal product, you notice an unintentional weight loss (not due to diet or exercise).

Other diseases

This medicinal product is not recommended if you have one or more of the following diseases:

  • severe immunological diseases such as HIV infection, multiple sclerosis (MS), systemic lupus erythematosus (SLE), or progressive multifocal leukoencephalopathy (PML)
  • severe acute infectious diseases such as acute hepatitis
  • cancer (except for patients with basal cell carcinoma, a type of slow-growing skin cancer)
  • or severe heart disease

There is limited experience with this medicinal product in these diseases. If you are diagnosed with any of these diseases, consult your doctor.

Experience with the use of this medicinal product in patients with a previous diagnosis of tuberculosis, viral hepatitis, viral herpes, or herpes zoster is also limited. Consult your doctor if you have any of these diseases.

Symptoms you should be aware of

During the first few weeks of treatment with roflumilast, you may experience diarrhea, nausea, abdominal pain, or headache. If these side effects do not disappear after the first few weeks of treatment, consult your doctor.

Roflumilast is not recommended in patients with a history of depression associated with suicidal ideation or behavior. You may also experience difficulty sleeping, anxiety, nervousness, or depression. Before starting treatment with roflumilast, inform your doctor if you suffer from any of these symptoms or if you are taking any other medicinal product that may increase the likelihood of these side effects. You or your caregivers should immediately inform your doctor about any change in behavior or mood and any suicidal thoughts you may have.

Children and adolescents

Do not give this medicinal product to children or adolescents under 18 years of age.

Other medicinal products and Roflumilast Aurovitas

Inform your doctor or pharmacist if you are using, have recently used, or might use any other medicinal products, especially the following:

  • a medicinal product containing theophylline (used to treat respiratory diseases), or
  • a medicinal product used to treat immunological diseases, such as methotrexate, azathioprine, infliximab, etanercept, or prolonged use of oral corticosteroids.
  • a medicinal product containing fluvoxamine (a medicinal product used to treat anxiety disorders and depression), enoxacin (a medicinal product used to treat bacterial infections), or cimetidine (a medicinal product used to treat stomach ulcers or acidity).

The effect of roflumilast may be reduced if combined with rifampicin (a type of antibiotic) or with phenobarbital, carbamazepine, or phenytoin (medicinal products used to treat epilepsy). Consult your doctor.

Roflumilast can be combined with other medicinal products for the treatment of COPD, such as bronchodilators and inhaled or oral corticosteroids. Do not stop taking these medicinal products or reduce their doses unless your doctor tells you to.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor or pharmacist before taking this medicinal product.

You should not become pregnant during treatment with this medicinal product and should use an effective contraceptive method during treatment, as roflumilast may be harmful to the fetus.

Driving and using machines

Roflumilast does not affect the ability to drive or use machines.

Roflumilast Aurovitas contains lactose

If your doctor has told you that you have an intolerance to some sugars, consult your doctor before taking this medicinal product.

3. How to take Roflumilast Aurovitas

Take this medicinal product exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.

  • During the first 28 days- the recommended initial dose is one 250 microgram tablet of roflumilast once daily.
  • The initial dose is a low dose that is used to help your body get used to the medicinal product before starting the full dose. With this low dose, you will not get the full effect of the medicinal product, so it is essential that you switch to the full dose (called the "maintenance dose") after 28 days.

This dosing regimen is not possible with Roflumilast Aurovitas. Roflumilast Aurovitas is only available in a 500 microgram tablet, which cannot be divided into two equal halves. For the administration of the initial 250 microgram dose, other presentations are available on the market.

  • After 28 days- the recommended maintenance dose is one 500 microgram tablet once daily.

Take the tablet with water. You can take it with or without food. Take it every day at the same time.

It may take several weeks for Roflumilast Aurovitas to produce its effect.

If you take more Roflumilast Aurovitas than you should

If you have taken more tablets than you should, you may experience the following symptoms: headache, nausea, diarrhea, dizziness, palpitations, confusion, mucous, and low blood pressure. Immediately consult your doctor, pharmacist, or call the Toxicology Information Service, phone 91 562 04 20. If possible, take the medicinal product and this leaflet with you.

If you forget to take Roflumilast Aurovitas

If you forget to take a tablet at the scheduled time, take it as soon as you remember on the same day. If you have forgotten to take it for the entire day, continue taking the normal dose the next day. Continue taking the medicinal product at the usual time. Do not take a double dose to make up for forgotten doses.

If you stop taking Roflumilast Aurovitas

It is essential that you continue taking Roflumilast Aurovitas for the period indicated by your doctor, even when you no longer have symptoms, to control lung function.

If you have any further questions on the use of this medicinal product, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicinal products, this medicinal product can cause side effects, although not everybody gets them.

You may experience diarrhea, nausea, stomach pain, or headache during the first few weeks of treatment with this medicinal product. Consult your doctor if these side effects do not resolve within the first few weeks of treatment.

Some side effects can be serious. In clinical studies and post-marketing experience, rare cases of suicidal thoughts and behaviors (including suicide) have been reported. Immediately inform your doctor of any suicidal thoughts you may have. You may also experience insomnia (frequent), anxiety (uncommon), nervousness (rare), panic attacks (rare), or depressive mood (rare).

In rare cases, allergic reactions may occur. Allergic reactions can affect the skin and, in rare cases, cause swelling of the eyelids, face, lips, and tongue, which can lead to difficulty breathing and/or a decrease in blood pressure and rapid heart rate. In case of an allergic reaction, stop taking roflumilast and immediately contact your doctor or go to the emergency department of the nearest hospital. Take all your medicinal products and this leaflet with you and provide all information about your current medication.

Other side effects include the following:

Common side effects: may affect up to 1 in 10 people

  • diarrhea, nausea, stomach pain
  • weight loss, decreased appetite
  • headache

Uncommon side effects: may affect up to 1 in 100 people

  • tremors, feeling of dizziness (vertigo), dizziness
  • feeling of rapid or irregular heartbeats (palpitations)
  • gastritis, vomiting
  • acid reflux from the stomach to the throat (acid regurgitation), indigestion
  • rash
  • muscle pain, muscle weakness, or cramps
  • back pain
  • feeling of weakness or fatigue; general malaise

Rare side effects: may affect up to 1 in 1,000 people

  • gynecomastia (enlargement of breast tissue in men);
  • loss of taste
  • respiratory tract infections (except pneumonia)
  • bloody stools, constipation
  • elevated liver and muscle enzymes (observed in blood tests)
  • hives (urticaria)

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Spanish Medicines Agency's website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicinal product.

5. Storage of Roflumilast Aurovitas

Keep this medicinal product out of the sight and reach of children.

This medicinal product does not require any special storage conditions.

Do not use this medicinal product after the expiry date which is stated on the carton and blister after EXP. The expiry date is the last day of the month stated.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

Composition of Roflumilast Aurovitas

  • The active substance is roflumilast. Each tablet contains 500 micrograms of roflumilast.
  • The other ingredients are: lactose monohydrate, corn starch, hypromellose (type 2910), poloxamer (type 188), magnesium stearate

Appearance and packaging

Tablet.

Uncoated white to off-white tablets, round, flat, with beveled edges, engraved with "T" and "500" on one side and smooth on the other side. [Size: approximately 5 mm].

Roflumilast Aurovitas tablets are available in blister packs.

Package sizes

Blister pack: 10, 14, 28, 30, 60, 84, 90, 98, and 100 tablets.

Not all pack sizes may be marketed.

Marketing authorisation holder and manufacturer

Marketing authorisation holder

Aurovitas Spain, S.A.U.

Avda. de Burgos, 16-D

28036 Madrid

Spain

Phone: 91 630 86 45

Fax: 91 630 26 64

Manufacturer

APL Swift Services (Malta) Limited

HF26, Hal Far Industrial Estate, Hal Far

Birzebbugia, BBG 3000

Malta

Or

Generis Farmacêutica, S.A.

Rua João de Deus, 19

2700-487 Amadora

Portugal

This medicinal product is authorised in the Member States of the European Economic Area under the following names:

Czech Republic: Roflumilast Aurovitas

Germany: RoflumilaPUREN 500 Mikrogramm Tabletten

Portugal: Roflumilaste Generis

Spain: Roflumilast Aurovitas 500 micrograms tablets EFG

Date of last revision of this leaflet: September 2020

Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).

Online doctors for ROFLUMILAST AUROVITAS 500 micrograms TABLETS

Discuss questions about ROFLUMILAST AUROVITAS 500 micrograms TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
Camera Book a video appointment
€58
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80
5.0 (25)
Doctor

Lina Travkina

Family medicine 13 years exp.

Dr. Lina Travkina is a licensed family and preventive medicine doctor based in Italy. She provides online consultations for adults and children, supporting patients across all stages of care – from acute symptom management to long-term health monitoring and prevention.

Areas of medical care include:

  • Respiratory conditions: colds, flu, acute and chronic bronchitis, mild to moderate pneumonia, bronchial asthma.
  • ENT and eye conditions: sinusitis, tonsillitis, pharyngitis, otitis, infectious and allergic conjunctivitis.
  • Digestive issues: gastritis, acid reflux (GERD), IBS, dyspepsia, bloating, constipation, diarrhoea, functional bowel symptoms, intestinal infections.
  • Urological and infectious diseases: acute and recurrent cystitis, bladder and kidney infections, prevention of recurrent UTIs, asymptomatic bacteriuria.
  • Chronic conditions: hypertension, diabetes, hypercholesterolemia, metabolic syndrome, thyroid disorders, excess weight.
  • Neurological and general symptoms: headache, migraine, dizziness, fatigue, sleep disturbances, reduced concentration, anxiety, asthenia.
  • Chronic pain support: back, neck, joint, and muscle pain, tension syndromes, pain associated with osteochondrosis and chronic conditions.

Additional care areas:

  • Preventive consultations and check-up planning.
  • Medical advice and follow-up consultations.
  • Test interpretation and diagnostic guidance.
  • Structured support for undiagnosed complaints.
  • Second opinion on diagnoses and treatment plans.
  • Nutritional and lifestyle support for vitamin deficiencies, anaemia, metabolic issues.
  • Post-operative recovery support and pain management.
  • Preconception counselling and postpartum support.
  • Immunity support and strategies to reduce frequency of infections.

Dr. Travkina combines evidence-based medicine with an attentive, personalised approach. Her consultations focus not only on treatment, but also on prevention, recovery, and long-term wellbeing.

If during the consultation it becomes clear that your case requires in-person assessment or specialised care outside of her scope, the session will be terminated and the payment fully refunded.

Camera Book a video appointment
€70
5.0 (764)
Doctor

Alina Tsurkan

Family medicine 13 years exp.

Dr. Alina Tsurkan is a licensed family medicine physician based in Portugal, offering online consultations for adults and children. She provides professional primary care, with a focus on prevention, accurate diagnosis, and long-term management of acute and chronic conditions.

Dr. Tsurkan supports patients with a wide range of health issues, including:

  • Respiratory infections: cold, flu, bronchitis, pneumonia, and lingering coughs.
  • ENT conditions: sinusitis, tonsillitis, otitis (ear infections), sore throat, allergic rhinitis.
  • Eye conditions: allergic or infectious conjunctivitis, red eyes, irritation.
  • Digestive issues: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), constipation, bloating, nausea.
  • Urinary and reproductive health: urinary tract infections (UTIs), cystitis, prevention of recurrent infections.
  • Chronic diseases: hypertension, elevated cholesterol, weight management.
  • Neurological complaints: headaches, migraines, sleep disturbances, fatigue, general weakness.
  • Children’s health: fever, infections, digestive issues, follow-ups, vaccination guidance.

She also provides:

  • IMT medical certificates for driving licence exchange in Portugal.
  • Personalised preventive care and wellness consultations.
  • Interpretation of test results and medical reports.
  • Follow-up care and medication review.
  • Support in managing multiple coexisting conditions.
  • Remote prescription management and medical documentation.

Dr. Tsurkan’s approach is evidence-based and holistic. She works closely with each patient to develop an individualised care plan that addresses both symptoms and root causes. Her goal is to empower patients to take control of their health and maintain well-being through lifestyle adjustments, routine check-ups, and early intervention.

Camera Book a video appointment
€55

Frequently Asked Questions

Is a prescription required for ROFLUMILAST AUROVITAS 500 micrograms TABLETS?
ROFLUMILAST AUROVITAS 500 micrograms TABLETS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in ROFLUMILAST AUROVITAS 500 micrograms TABLETS?
The active ingredient in ROFLUMILAST AUROVITAS 500 micrograms TABLETS is roflumilast. This information helps identify medicines with the same composition but different brand names.
How much does ROFLUMILAST AUROVITAS 500 micrograms TABLETS cost in pharmacies?
The average pharmacy price for ROFLUMILAST AUROVITAS 500 micrograms TABLETS is around 34.69 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures ROFLUMILAST AUROVITAS 500 micrograms TABLETS?
ROFLUMILAST AUROVITAS 500 micrograms TABLETS is manufactured by Aurovitas Spain, S.A.U.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of ROFLUMILAST AUROVITAS 500 micrograms TABLETS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether ROFLUMILAST AUROVITAS 500 micrograms TABLETS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to ROFLUMILAST AUROVITAS 500 micrograms TABLETS?
Other medicines with the same active substance (roflumilast) include DAXAS 250 micrograms tablets, DAXAS 500 micrograms FILM-COATED TABLETS, ROFLUMILAST AUROVITAS 250 micrograms TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media